Inicio・Lista de Acciones・Arvinas Inc

Arvinas Inc

Cerrado

SectorSanidad

8.24 -0.48

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

7.87

Máximo

8.28

Métricas clave
By Trading Economics
Ingresos	9.8M -58M
Ventas	6.1M 16M
BPA	-0.9
Margen de beneficios	-369.231
Empleados	246
EBITDA	9.6M -56M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+82.81% upside

Dividendos
By Acuity
Próximas Ganancias	5 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-106M 517M
Apertura anterior	8.72
Cierre anterior	8.24

Noticias sobre sentimiento de mercado

By Acuity

60%

40%

284 / 340 Clasificación en Healthcare

Arvinas Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 jul 2026, 20:06 UTC

Arvinas Inc shares are higher during Tuesday's session, tracking gains in the Nasdaq 100 Index amid strong technology sector performance. No specific news was identified.

Comparación entre iguales

Cambio de precio

Arvinas Inc previsión

Precio Objetivo

By TipRanks

82.81% repunte

Estimación a 12 Meses

Media 15.1 USD 82.81%

Máximo 24 USD

Mínimo 6 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Arvinas Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

11 ratings

Comprar

Mantener

Vender

De acuerdo con 11 analistas que ofrecen calificaciones bursátiles a para Arvinas Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

284 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Arvinas Inc

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.